BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Hospital For Special Surgery Ventures, Radius Ventures, And Elron Electronics Lead $18 Million Financing Round For Impliant


10/19/2005 5:12:04 PM

MILFORD, Conn., Jan. 9 /PRNewswire/ -- Impliant Inc., a developer of novel posterior motion-preservation and cartilage-protection devices for spine and joint arthroplasty, today announced it has secured more than $18 million in Series C financing from a group of leading financial and strategic investors. New investors HSS Ventures, an affiliate of the Hospital for Special Surgery, Radius Ventures, and Elron Electronic Industries Ltd. participated in the round alongside Impliant's existing investors-Advent International, Gemini Israel Funds and InnoMed Ventures.

Through its use of cutting-edge polymer materials and engineering techniques, Impliant is developing a new class of spine and joint arthroplasty devices, which target significant portions of the $20 billion orthopedic implant market. The TOPS(TM) System-the world's first Total Posterior Spine system-addresses the 300,000 patients undergoing fusion surgery who could benefit from a posterior motion preservation system. The company's Cushion- Bearing(TM) joint implants fulfill the need among baby boomers for partial hip, knee and shoulder prostheses.

Ron Sacher, CEO of Impliant, said, "The strong interest from such high- quality investors demonstrates the enormous potential of our products, which we believe will revolutionize the field of spine and joint arthroplasty. This current round of financing enables Impliant to complete clinical trials, gain regulatory approvals and begin marketing our TOPS(TM) System, while advancing our line of Cushion-Bearing(TM) joint arthroplasty devices."

Paddy Mullen, Managing Director of HSS Ventures, an affiliate of Hospital for Special Surgery that is focused on product development, technology incubation and venture investing said, "Impliant's posterior motion preservation solution is an impressive design offering a promising alternative to fusion."

Jordan Davis, Managing Partner at Radius Ventures, commented, "The TOPS(TM) System has strong potential to be the first motion-preserving spine implant that broadly addresses multiple sources of posterior back pain. This elegant technology resonates well with leading spine surgeons."

Ann Bilyew, a Partner at Advent International, which has been an investor in Impliant since 2001, said, "We are enthusiastic about Impliant's progress to date and potential for advancing its current programs through clinical trials. Our latest investment, which comes from our newest HCLS III fund, is based on the tremendous promise the company has shown in developing a new generation of cushion-bearing joint and spine implants."

For more information contact: Ron Sacher Impliant Inc. (917) 270-5538 rsacher@impliant.com

Impliant Inc. is developing a line of innovative spine and joint arthroplasty implants. In 1999, Gemini Israel Funds led Impliant's Series A financing round, while the Series B financing round was led by Advent International and Innomed. For more information on the company, visit http://www.impliant.com/.

Impliant Inc.

CONTACT: Ron Sacher of Impliant Inc., +1-917-270-5538,rsacher@impliant.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES